Cargando…
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
Evaluation of Anagrelide (Xagrid(®)) Efficacy and Long-term Safety, a phase IV, prospective, non-interventional study performed in 13 European countries enrolled high-risk essential thrombocythemia patients treated with cytoreductive therapy. The primary objectives were safety and pregnancy outcomes...
Autores principales: | Birgegård, Gunnar, Besses, Carlos, Griesshammer, Martin, Gugliotta, Luigi, Harrison, Claire N., Hamdani, Mohamed, Wu, Jingyang, Achenbach, Heinrich, Kiladjian, Jean-Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777190/ https://www.ncbi.nlm.nih.gov/pubmed/29079600 http://dx.doi.org/10.3324/haematol.2017.174672 |
Ejemplares similares
-
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016) -
Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2012) -
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008) -
Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia
por: Song, David, et al.
Publicado: (2023) -
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
por: Gotic, Mirjana, et al.
Publicado: (2020)